The latest study indicated that TME subtypes of HCC are associated to the immunotherapy efficacy by combining spatial transcriptomics with single-cell RNA sequencing (scRNA-seq) and multiplexed immunofluorescence of anti-PD-1-treated HCC patients (111). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.